Signature Estate & Investment Advisors’s AbCellera Biologics ABCL Stock Holding History

Signature Estate & Investment Advisors’s Portfolio ABCL Stock Details ABCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-35,668	Closed	-$124K	–	670
2026 Q1	$124K	Hold	35,668	–	–	﹤0.01%	637
2025 Q4	$122K	Sell	35,668 -3,000	-8%	-$13.4K	﹤0.01%	598
2025 Q3	$195K	Sell	38,668 -1,000	-3%	-$4.41K	﹤0.01%	582
2025 Q2	$136K	Hold	39,668	–	–	﹤0.01%	565
2025 Q1	$88.5K	Hold	39,668	–	–	﹤0.01%	542
2024 Q4	$116K	Hold	39,668	–	–	﹤0.01%	527
2024 Q3	$103K	Hold	39,668	–	–	﹤0.01%	515
2024 Q2	$117K	Buy	+39,668	New	+$150K	﹤0.01%	496

Other funds holding ABCL

TWC

TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return

CMF

Counterpoint Mutual Funds San Diego, California $1.01B AUM 37.65% 1-Year Est. Return

Guardian Partners Toronto, Canada $1.11B AUM 38.73% 1-Year Est. Return

SOMRS

State of Michigan Retirement System Lansing, Michigan $22.6B AUM 40.24% 1-Year Est. Return

DRP

Decker Retirement Planning Levi, Utah $294M AUM 97.44% 1-Year Est. Return

Daiwa Securities Group Tokyo, Japan $51.1B AUM 35.55% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return

CPC

Cookson Peirce & Co Pittsburgh, Pennsylvania $3.04B AUM 94.11% 1-Year Est. Return

Signature Estate & Investment Advisors's ABCL Position: Q2 2026 in Review

Signature Estate & Investment Advisors sold out of AbCellera Biologics (ABCL) in Q2 2026, closing a stake of 35,668 shares — an estimated $124K sold.

Signature Estate & Investment Advisors first reported a position in ABCL in Q2 2024 and held it in 8 quarters. The position peaked at $195K in Q3 2025. 55 funds tracked by Wall St. Rank hold ABCL as of Q2 2026.

Signature Estate & Investment Advisors reported no remaining AbCellera Biologics position as of Q2 2026 after selling out during the quarter.
Signature Estate & Investment Advisors sold 35,668 AbCellera Biologics shares in Q2 2026, an estimated $124K.
Signature Estate & Investment Advisors first reported a position in AbCellera Biologics in Q2 2024 and held it in 8 quarters.
Signature Estate & Investment Advisors's AbCellera Biologics position peaked at $195K in Q3 2025.
55 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2026.

Based on Signature Estate & Investment Advisors's 13F filing for Q2 2026, filed 14 Jul 2026.